Please ensure Javascript is enabled for purposes of website accessibility

Nasdaq Today: Why Alexion and Workday Stock Are Soaring

By Dan Caplinger – May 28, 2020 at 2:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stocks in the Nasdaq were generally higher, but these two stood out.

The stock market continued to gain ground at midday on Thursday, and the Nasdaq Composite (^IXIC) participated in the modest rally. Slightly before noon EDT, the index was up just over half a percent, as was the Nasdaq 100 Index of top stocks on the exchange. There's been rising enthusiasm lately about the prospects for the U.S. economy to escape the full brunt of what many economists have feared from the fallout from coronavirus-inspired shutdowns. Today's move continued the upward momentum from that newfound optimism.

Also helping to keep stocks moving forward was good news from several individual stocks. Workday (WDAY 0.03%) and Alexion Pharmaceuticals (ALXN) rose for different reasons, but their gains were among the leaders in the Nasdaq 100 and showed the broad-based support that the rally has had recently.

Working for a living

Shares of Workday rose 8% at midday on Thursday. The cloud-based human resources and finance enterprise application provider reported first-quarter financial results that showed continued growth, albeit over reduced expectations from investors.

Side of office building with Workday logo on the top floor.

Image source: Workday.

Workday's revenue for the first quarter was up 23% from year-ago levels, topping the $1 billion mark. Subscription-based revenue rose at a faster 26% clip. Although Workday continued to lose money, its per-share losses were largely in line with last year's results on an adjusted basis, and operating cash flow improved from prior-year levels.

Investors were pleased to see not only that Workday's retention among existing customers was good but also that it picked up some major new customers as well, including several members of the Fortune 500 company list. Workday CEO Aneel Bhusri celebrated his own workforce's ability to work remotely to keep delivering advanced features on its cloud platform for the benefit of enterprise clients.

Even with a slight pullback in full-year revenue projections, Workday still gave investors what they wanted to hear. The power of the cloud has become clearer during the coronavirus crisis, and shareholders expect Workday to keep delivering strong results.

Alexion hopes for a win

Shares of Alexion Pharmaceuticals rose 7% at midday Thursday. The upward move reflected hopes among investors that a shadow hanging over the stock might soon lift.

Alexion has been engaged in a court battle with Amgen (AMGN -1.23%) over the rights to the immunosuppressant Soliris, which is Alexion's top-selling drug. Amgen is looking to develop a biosimilar version of Soliris, which would threaten that revenue.

Late yesterday, filings with the patent court that's hearing the case indicated that Alexion and Amgen had reached a settlement in principle. Although the specific terms weren't included in the court documents, investors were pleased at the idea that Alexion might have evaded the threat of a sizable loss of revenue.

Alexion shareholders won't know for sure until details become available. For now, though, optimism about a resolution has investors pleased with the biotech stock.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Workday. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Workday Stock Quote
$159.50 (0.03%) $0.05
Alexion Pharmaceuticals Stock Quote
Alexion Pharmaceuticals
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$11,148.64 (%)
Amgen Inc. Stock Quote
Amgen Inc.
$230.94 (-1.23%) $-2.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.